KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Return on Capital Employed (2016 - 2026)

Pacira BioSciences has reported Return on Capital Employed over the past 16 years, most recently at 2.14% for Q1 2026.

  • For Q1 2026, Return on Capital Employed rose 888.0% year-over-year to 2.14%; the TTM value through Mar 2026 reached 2.14%, up 888.0%, while the annual FY2025 figure was 1.49%, 734.0% up from the prior year.
  • Return on Capital Employed for Q1 2026 was 2.14% at Pacira BioSciences, up from 1.65% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 7.0% in Q1 2024 and troughed at 8.35% in Q2 2025.
  • A 5-year average of 1.63% and a median of 3.17% in 2025 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: crashed -1442bps in 2025 and later surged 888bps in 2026.
  • Year by year, Return on Capital Employed stood at 3.85% in 2022, then surged by 56bps to 6.02% in 2023, then plummeted by -199bps to 5.98% in 2024, then soared by 128bps to 1.65% in 2025, then increased by 29bps to 2.14% in 2026.
  • Business Quant data shows Return on Capital Employed for PCRX at 2.14% in Q1 2026, 1.65% in Q4 2025, and 3.17% in Q3 2025.